Skip to main content

Agendia Closes Second Financing Round; Undisclosed Amount Higher Than Series A

NEW YORK, Oct. 11 (GenomeWeb News) - Dutch diagnostics firm Agendia has closed a second round of financing worth "double-digit" millions of dollars to accelerate the development of microarray-based late-stage products into diagnostic tests, the company said today.


An Agendia spokesperson declined to provide a specific amount, but said that the financing improved upon the company's Series A round, which closed in March 2004.


The financing round was led by existing investors Gilde, AXA, and GLSV, and new investor Van Herk Group.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.